Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 2, 2012, Pages 838-844

  Sakoulas, George ^a   Bayer, Arnold S ^b,c   Pogliano, Joseph ^a   Tsuji, Brian T ^d   Yang, Soo Jin ^b   Mishra, Nagendra N ^b   Nizet, Victor ^a   Yeaman, Michael R ^b,c   Moise, Pamela A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIMICROBIAL CATIONIC PEPTIDE; BETA LACTAM; DAPTOMYCIN; LINEZOLID; POLYLYSINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BLOOD CULTURE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG SENSITIVITY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; EXAMINATION; FLOW CYTOMETRY; GROWTH INHIBITION; HOST RESISTANCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SURFACE CHARGE;

AMPICILLIN; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTEREMIA; BETA-LACTAMS; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; ENTEROCOCCUS FAECIUM; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; TREATMENT OUTCOME; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 84862965144     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05551-11     Document Type: Article

References (49)

1. al-Obeid S, Gutmann L, Williamson R. 1990. Correlation of penicillin-induced lysis of Enterococcus faecium with saturation of essential penicillin-binding proteins and release of lipoteichoic acid. Antimicrob. Agents Chemother. 34:1901-1907. (Pubitemid 20290287)
2. Arias CA, et al. 2011. Genetic bases for in vivo daptomycin resistance in enterococci. N. Engl. J. Med. 365:892-900.
3. Bingen E, Lambert-Zechovsky N, Leclercq R, Doit C, Mariani-Kurkdjian P. 1990. Bactericidal activity of vancomycin, daptomycin, ampicillin, and aminoglycosides against vancomycin-resistant Enterococcus faecium. J. Antimicrob. Chemother. 26:619-626.
4. Blaser J. 1985. In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. J. Antimicrob. Chemother. 15(Suppl. A):125-130. (Pubitemid 15079556)
5. Cashman KA, Bayer AS, Yeaman MR. 1998. Diversity in susceptibility to antibiotics and cationic peptides among Enterococcus faecalis or Enterococcus faecium isolates of diverse clinical or geographic origin, abstr. A-26. Abstr. 98th Gen. Meet. Am. Soc. Microbiol., Atlanta, GA. American Society for Microbiology, Washington, DC.
6. Cashman KA, Hooper DC, Bayer AS, Koo SP, Yeaman MR. 1999. In vitro resistance to vancomycin and endogenous cationic antimicrobial peptides are independent phenotypes in clinical isolates of Enterococcus faecium, abstr. A-93.Abstr. 99th Gen. Meet. Am. Soc. Microbiol., Chicago, IL. American Society for Microbiology, Washington, DC.
7. Cashman KA, Bayer AS, Yeaman MR. 1999. Diversity of platelet microbicidal protein susceptibility in Enterococcus. California State University Press, Long Beach, CA.
8. Cilli F, Aydemir S, Tunger A. 2006. In vitro activity of alone and in combination with various antimicrobials against Gram-positive cocci. J. Chemother. 18:27-32.
9. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
10. Courvalin P. 2006. Vancomycin resistance in Gram-positive cocci. Clin. Infect. Dis. 42(Suppl. 1):S25-S34. (Pubitemid 41832062)
11. Cubist Pharmaceuticals. 2010. Daptomycin for injection, package insert. Cubist Pharmaceuticals, Lexington, MA.
12. Dhand A, et al. 2011. Use of anti-staphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus (MRSA): role of enhanced daptomycin binding. Clin. Infect. Dis. 53:158-163.
13. Duez JM, Pechinot A, Siebor E, Cordin X, Kazmierczak A. 1989. Bactericidal activity of daptomycin and vancomycin alone or in combination with tobramycin, netilmicin or ampicillin against Enterococcus. Pathol. Biol. (Paris) 37:263-268. (Pubitemid 19119504)
14. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother. 47:1318-1323. (Pubitemid 36368592)
15. Entenza JM, Giddey M, Vouillamoz J, Moreillon PP. 2010. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int. J. Antimicrob. Agents 35:451-456.
16. Fabretti F, et al. 2006. Alanine esters of enterococcal lipoteichoic acid play a role in biofilm formation and resistance to antimicrobial peptides. Infect. Immun. 74:4164-4171. (Pubitemid 43993350)
17. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
18. Foulds G. 1986. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev. Infect. Dis. 8(Suppl. 5):S503-S511.
19. Harigaya Y, et al. 2009. Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob. Agents Chemother. 53:3894-3901.
20. Hayden MK, et al. 2005. Development of daptomycin resistance in vivo in methicillin-resistant Staphyloccus aureus. J. Clin. Microbiol. 43:5285-5287. (Pubitemid 41484040)
21. Hirschwerk D, Ginocchio CC, Bythrow M, Condon S. 2006. Diminished susceptibility to daptomycin accompanied by clinical failure in a patient with methicillin-resistant Staphylococcus aureus bacteremia. Infect. Control Hosp. Epidemiol. 27:315-317.
22. Jones T, et al. 2008. Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding. Antimicrob. Agents Chemother. 52:269-278.
23. Julian K, et al. 2007. Characterization of a daptomycin-nonsusceptible, vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. Antimicrob. Agents Chemother. 51:3445-3448. (Pubitemid 350067576)
24. Kelesidis T, Humphries R, Uslan DZ, Pegues DA. 2011. Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. Clin. Infect. Dis. 52:228-234.
25. Reference deleted.
26. Lewis JS, et al. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob. Agents Chemother. 41:1664-1665.
27. Mangili A, Bica I, Snydman DR, Hamer DH. 2005. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin. Infect. Dis. 40:1058-1060. (Pubitemid 40418318)
28. Mariani PG, Sader HS, Jones RN. 2006. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. J. Antimicrob. Chemother. 58:481-483. (Pubitemid 44294975)
29. Marty FM, et al. 2006. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis. J. Clin. Microbiol. 44:595-597. (Pubitemid 43224254)
30. Mobarakai N, Quale JM, Landman D. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387. (Pubitemid 24054271)
31. Moise PA, North D, Steenbergen JN, Sakoulas G. 2009. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect. Dis. 9:617-624.
32. Montero CI, Stock F, Murray PR. 2008. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob. Agents Chemother. 52:1167-1170. (Pubitemid 351358408)
33. Mukhopadhyay K, et al. 2007. In vitro susceptibility of Staphylococcus aureus to thrombin-induced platelet microbicidal protein-1 (tPMP-1) is influenced by cell membrane phospholipid composition and asymmetry. Microbiology 153:1187-1197. (Pubitemid 46605817)
34. Palmer KL, Daniel A, Hardy C, Silverman J, Gilmore MS. 2011. Genetic bases for daptomycin resistance in enterococci. Antimicrob. Agents Chemother. 55:3345-3356.
35. Reference deleted.
36. Pogliano J, et al. 1999. A vital stain for studying membrane dynamics in bacteria: a novel mechanism controlling septation during Bacillus subtilis sporulation. Mol. Microbiol. 31:1149-1159. (Pubitemid 29082244)
37. Rand KH, Houck H. 2004. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J. Antimicrob. Chemother. 53:530-532. (Pubitemid 38380256)
38. Seidl K, et al. 2011. Combinatorial phenotypic signatures distinguish persistent from resolving methicillin-resistant Staphylococcus aureus bacteremia isolates. Antimicrob. Agents Chemother. 55:575-582.
39. Skiest DJ. 2006. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J. Clin. Microbiol. 44:655-656. (Pubitemid 43222276)
40. Tsuji BT, Rybak MJ. 2005. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 49:2735-2745. (Pubitemid 40917586)
41. Vikram HR, Havill NL, Koeth M, Boyce JM. 2005. Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin. J. Clin. Microbiol. 43:5384-5387. (Pubitemid 41484067)
42. Xiong YQ, Yeaman MR, and Bayer AS. 1999. In vitro microbicidal activities of thrombin-induced platelet microbicidal protein-1 and human neutrophil defensin-1 on Staphylococcus aureus are substantially influenced by pretreatment with antibiotics differing in mechanisms of action. Antimicrob. Agents Chemother. 43:1111-1117. (Pubitemid 29214733)
43. Xiong YQ, Mukhopadhyay K, Yeaman MR, Adler-Moore J, Bayer AS. 2005. Functional interrelationships between cell membrane and cell wall in antimicrobial peptide-mediated killing of Staphylococcus aureus. Antimicrob. Agents Chemother. 49:3114-3121. (Pubitemid 41060548)
44. Yang SJ, et al. 2010. Daptomycin-oxacillin combinations in experimental methicillin-resistant Staphylococcus aureus (MRSA) endocarditis caused by daptomycin-nonsusceptible strains with evolving oxacillin susceptibility ("see-saw effect"). Antimicrob. Agents Chemother. 54:3161-3169.
45. Yeaman MR, Gank KD, Bayer AS, Brass EP. 2002. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46:3883-3891. (Pubitemid 35403265)
46. Yeaman MR, Norman DC, Bayer AS. 1992. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob. Agents Chemother. 36:1665-1670.
47. Yeaman MR. 2002. Code among chaos in antimicrobial resistance: lessons from host defense proteins, p 10. Keystone Symposium on Molecular and Cellular Biololgy, Santa Fe, NM. Keystone Symposia, Silverthorne, CO.
48. Yeaman MR, Sullam PM, Dazin PF, Bayer AS. 1994. Platelet microbicidal protein alone and in combination with antibiotics reduces Staphylococcus aureus adherence to platelets in vitro. Infect. Immun. 62:3416-3423. (Pubitemid 24232128)
49. Yeaman MR, Yount NY. 2003. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 55:27-55. (Pubitemid 36268398)